Prospective observational study reveals unbound ceftolozane and tazobactam pharmacokinetics in critically ill patients without renal dysfunction, highlighting the adequacy of standard dosing regimens.
Evaluation of dosing regimens for critically ill patients requires pharmacokinetic data in this population. This prospective observational study aimed to describe the population pharmacokinetics of unbound ceftolozane and tazobactam in critically ill patients without renal impairment and to assess the adequacy of recommended dosing regimens for treatment of systemic infections. Patients received 1.5 or 3.0 g ceftolozane-tazobactam according to clinician recommendation.
No takes yet. Share an insight, caveat, or question.
Sime et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: